A study of lymph node ratio in stage IV colorectal cancer by Kristoffer Derwinger & Bengt Gustavsson
BioMed Central
World Journal of Surgical Oncology
ssOpen AcceResearch
A study of lymph node ratio in stage IV colorectal cancer
Kristoffer Derwinger* and Bengt Gustavsson
Address: Department of Surgery, Sahlgrenska University Hospital/Östra, Gothenburg, Sweden
Email: Kristoffer Derwinger* - kristoffer.derwinger@vgregion.se; Bengt Gustavsson - bengt.gustavsson@surgery.gu.se
* Corresponding author    
Abstract
Background: The finding of metastasis in colorectal cancer, stage IV disease, has a major impact
on prognosis and treatment strategy. Known important factors include the extent of the metastasis
and the patients' performance status. The lymph node factors are of known importance in earlier
cancer stages but less described in metastatic disease. The aim of the study was to evaluate lymph
node status and ratio as prognostic markers in stage IV colorectal cancer.
Methods: The study was retrospective and assessing all patients operated, with bowel resection,
for an initial stage IV colorectal cancer during 1999–2003 (n = 136). Basic demographic data as well
as given treatment was assessed. The Lymph node ratio (LNR), the quota between the number of
lymph node metastasis and assessed lymph nodes, was calculated. LNR groups were created by
ratio thirds, 3 equally sized groups. The analysis was made by LNR group and by eligibility for
chemotherapy with cancer specific survival as outcome parameter.
Results: The median survival (CSS) for the entire group was 431 days with great variability. For
the patients eligible for chemotherapy it ranged from 791 days in LNR-group 1 to 433 days for the
patients in group 3. For patients ineligible for chemotherapy the corresponding figures were 209
and 91 days. The eligibility for chemotherapy was a major prognostic factor which also takes co-
morbidity, age and performance status into consideration. The LNR (p < 0.01) and the tumour
differentiation grade were also significant (p < 0.05) factors regarding survival. The LNR group 3
was also associated with a higher frequency of multiple metastasis locations (p < 0.05) and of more
side effects with chemotherapy and thus of reductions in dosage or pre-emptive treatment ending
(p < 0.05).
Conclusion: Stage IV colorectal cancer is a heterogeneous group regarding the survival prognosis.
The lymph node ratio was found to be a significant marker for the survival prognosis (p < 0.0049).
High and low risk groups could be identified with a survival difference of up to one year. It could
be of importance when planning a treatment strategy or evaluating clinical data materials. A
pathology report should include a node assessment even at presence of synchronous metastasis.
Background
In Sweden about 5500 new colorectal cancers are diag-
nosed each year [1]. It is one of the more common forms
of cancer and the incidence is slowly increasing. The main
form of treatment is the surgical removal of the tumour.
Preceding the operation there are preoperative investiga-
tions. The aim is ruling out findings that can alter the
treatment strategy such as extra-intestinal manifestations
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continued intra-operatively and ultimately completed
post-operatively by the pathologists' analysis [2,3]. The
cancers are staged and classified according to the UICC/
AJCC standards of the TNM-system [4]. Almost 20% of
the patients are of stage IV disease, characterized by either
distant metastasis or by local overgrowth to adjacent
organs, at the time of diagnosis [5].
An accurate cancer staging is not only a foundation in
deciding treatment strategy but also an important prog-
nostic tool [6]. When metastases or locally advanced
growth are found there are several options that normally
are discussed in a multidisciplinary team conference.
These include the indication and timing of both surgery
and chemotherapy and also the possible treatment of the
metastasis. There is also the decision if it is possible to try
for a curative intent or if a palliative strategy is the only
option. There are indications for surgical resections, such
as bleeding and obstruction, even in the palliative situa-
tion. All available prognostic information that can aid in
this strategic decision-making is of clinical importance.
Major surgery can have negative effects for the patient and
the risk should be considered against the chance of poten-
tial benefit. The decisions are normally re-evaluated as the
time and treatment progress and new data can get availa-
ble.
There are known prognostic factors in stage IV disease
such as the patients performance status, the number of
metastatic organs and the tumour differentiation grade
[5]. In the earlier colorectal cancer stages (I-III) there is a
great prognostic interest in the lymph node assessment
and status. Different lymph node related factors as size,
distribution, numbers and even the number of assessed
lymph nodes are considered as possible aids in prediction
of prognosis [5,7,8]. Another possibility is by the lymph
node ratio which is highly significant in stage III disease
[9,10]. One problem is that these are only available after
surgical resections. However, when available, they could
add information and assist in the reassessments before the
continued treatment. The lymph node factors are not as
well studied in stage IV and also less frequently reported.
The aim of the study was to evaluate lymph node status
and ratio as prognostic markers in stage IV colorectal can-
cer.
Methods
At the department of surgery, Sahlgrenska/Östra Univer-
sity Hospital, Gothenburg we are continuously making a
registration of detailed clinical and pathological data. The
registration is consecutive since 1999 for all patients
treated at our unit for colorectal cancer. The study and reg-
istration was approved by the local Ethics committee and
all the patients have given their written informed consent.
Included in the database is also a continuous follow-up
regarding treatment and survival. During the period
1999–2003, 198 patients were surgically treated for an
initial stage IV colorectal cancer. The specimen had been
assessed by the pathologist for the lymph node status in
136 patients, who were then included into the study. All
had been operated with a surgical resection of the bowel
tumour. We retrieved basic clinical parameters as gender,
age, diagnosis, cancer location, performance status (PS)
and type of operation. Treatment data with the use of
chemotherapy, tolerability and side-effects was also con-
sidered as well as the number and location of the metas-
tasis. We acquired the pathology data including the
assessment of lymph nodes and differentiation grade. The
lymph node ratio (LNR) was calculated as the quota
between metastasis positive nodes and number of
assessed lymph nodes. The LNR-groups were created by
dividing the material into 3 equally sized groups, thus by
ratio thirds, to have a possibility of identifying high/low
risk groups. Survival data as well as treatment information
was also retrieved. As the outcome parameter we used the
cancer specific survival (CSS). Survival was assessed both
by ratio groups and by eligibility for chemotherapy. A
comparison was also made between LNR and N-status.
We used the JMP 4/SAS software for statistical analysis
(SAS institute). The basic patient demographic data was
set by distribution statistics with ANOVA or contingency
tables for non-parametric statistics. The Kaplan-Meier
method was used for univariate survival analysis and Log
rank test was used to compare survival differences
between the groups. The same analyses were made for
TNM N-status as well as differentiation grade. We made a
second analysis of the data for all patients who had had a
full pathology assessment of at least 12 nodes as by UICC/
AJCC recommendation to ensure validity. We also per-
formed a Cox multivariate analysis including PS, differen-
tiation grade, tumour location, age, given therapy,
metastatic burden and also the lymph node factor. The
later assessed both for the N-status and as LNR.
Results
The surgery and staging
The median age was 70 years with an equal gender distri-
bution. The most frequently performed operations were
the right hemicolectomy and the Hartman procedures.
The most common indications for surgery in this patient
group were bleeding or obstruction, the latter often result-
ing in resection and stoma formation. The preoperative
work-up was done with chest x-ray and liver ultrasonogra-
phy or CT-scan and were completed in 98% of elective
cases. 7 patients had lung metastasis only and 87 patients
had liver metastasis. An additional 14 patients had growth
in both organs. Of the remaining 28 patients were 24 had
emergency procedures and were classified as stage IV by
an intra-operative finding of metastases. The remaining 4
patients were assessed as possible spread by the radiolo-Page 2 of 6
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from specimen and intra-operative biopsies.
The pathology
The patient and pathology data are presented in table 1.
The differentiation grade correlated significantly with the
LNR group (p < 0.001). With a poor differentiation grade
is was more common to have a higher number of meta-
static nodes and also higher ratios. This also showed in the
distribution of TNM N1 and N2. The median number of
assessed nodes was 10 with a median of 4 metastasis pos-
itive nodes. There were only 2 patients without discovered
lymph node metastasis and both had had very few
assessed lymph nodes. We also found that with higher
LNR-group it was increasingly more frequent with multi-
ple metastasis locations (p < 0.05).
Chemotherapy
The treatment strategy was discussed in a multidiscipli-
nary team conference including the possible use of chem-
otherapy. 77 of the patients were eligible for
chemotherapy. The main reasons for ineligibility for
chemotherapy were age, concomitant disease or poor per-
formance status. All chemotherapy was given postopera-
tively. The common first line regime was 5-FU and
Leucovorin which accounted for more than 85% of the
given treatments. Second line chemotherapy, mainly
using Campto and Oxaliplatin regimes, were given to 47
patients. The main reasons for termination of chemother-
apy were toxicity or progression of the disease. Only 7
patients, of whom the majority had single metastasis,
were later treated for the liver metastasis by radiofre-
quency ablation or surgical resection. Only one achieved
long-term survival. We also noted that higher LNR-group
and foremost group 3 had significantly more problems
during the chemotherapy (p < 0.05). This showed by
more adverse effects, lower tolerability and more fre-
quently early treatment termination.
The survival prognostics
The median survival (CSS) for the entire group was 431
days with variability as shown in table 2. For the patients
eligible for chemotherapy it ranged from 791 days in LNR-
group 1 to 433 days for the patients in group 3. For
patients ineligible for chemotherapy the corresponding
figures were 209 and 91 days. In the univariate analysis
the lymph node ratio was significant (p < 0.0049) were a
higher quota corresponded with a worse prognosis (figure
1). The node status (N1–N2) had borderline significance
(p < 0.06) for survival prognostics with N2 (more than 3
positive nodes) corresponding to a worse prognosis. The
differentiation grade was also a significant factor (p <
0.001) where a poor grade corresponded to a worse prog-
nosis. There were no significant differences in survival
related to gender, diagnosis or cancer location. The eligi-
bility for chemotherapy was highly significant (p < 0.001)
but also contains factors as age and performance status.
All survival results retained their significance when redo-
ing the analysis for patients with at least 12 assessed
nodes. In the Cox analysis the performance status and eli-
gibility for chemotherapy was the most significant (HR
2.2 (1.1–4.3), p < 0.001) along with the differentiation
grade (HR 2.0 (1.1–2.8), p < 0.05). Concerning the lymph
nodes the LNR retained significance as a marker (HR 2.1
(1.3–3.6), p < 0.05) whilst the lymph node N-status was
not significant.
Discussion
The preoperative staging process has the aim of identify-
ing the patients with metastatic disease. A positive finding
has a major impact on the individual and does often lead
to changes in the treatment strategy. The findings are usu-
ally discussed at a multi-modal treatment conference [11].
The first decision is the role and timing of the different
treatment options. It is in many instances based on the
radiological picture combined with the general health of
the patient. The commonly used treatment in stage IV dis-
ease is chemotherapy, either as a palliative regime or as an
attempt to downstage the tumour in preparation for sur-
gery [12]. A strategy with curative intention can be
attempted for some patients. There are chances of long-
term survival and especially if the metastasis is solitary
[13]. The liver metastasis can be treated by hepatic resec-
tions or radio-frequency ablations and pulmonary metas-
tasis can be operated if unilateral [14].
Table 1: Patient demography and pathology by lymph node ratio group
LNR group Ratio/Node quota N Differentiation grade 
(well/med./poor)
N-status (N1/N2) Lymph nodes (median) Chemotherapy 
eligibility (yes/no)
Assessed Positive
1 0–0.15 46 4/36/6 46/0 10 (1–19) 1 (0–3) 27/19
2 0.16–0.65 45 3/30/12 15/30 10 (4–21) 4 (1–11) 23/22
3 0.66–1 45 0/14/31 6/39 9 (2–32) 8 (2–26) 27/18
Total 0–1 136 7/80/49 67/69 10 (1–32) 4 (0–26) 77/59Page 3 of 6
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static growth must be of a certain size to be detectable by
radiology. Thus, there could be an uncertainty about the
total tumour situation. The treatment decisions are often
re-evaluated as new data gets available. The response to
chemotherapy, with a possible down-staging effect, and
the postoperative pathology report are among these
important data. There are several known prognostic fac-
tors that should be considered [15]. The patients' general
health and performance status are important along with
the associated eligibility for chemotherapy. The CEA lev-
els and the tumour differentiation grade can also be of
interest [5,16,17]. The decision-making should balance
the possibility of gaining long-term survival against the
risk of complications, worsening the outcome and
decrease in quality of life.
The most common role of surgery in stage IV is local con-
trol. The indications are then to prevent profuse blood-
loss, to relieve obstruction or as a removal of mass
[18,19]. A drawback is the associated risk of complica-
tions and the possibly prolonged hospital stay [20]. This
has led to an increasing use of stents and thus a possibility
of relieving obstruction without surgery [21]. For the
patients that are ineligible for chemotherapy the progno-
sis is very poor (table 2). This concurs with our data and
supports the idea that the non-surgical options are prefer-
able for this group. Another important surgical indication
is as the first step in an attempt to achieve long term sur-
vival. For colon cancer it is often preferable to start with
the removal of the bowel tumour. The metastasis is then
treated either simultaneously or as a second procedure.
After surgery we gain access to more information about
the tumour status through the pathology report.
Included in the pathology report are the tumour differen-
tiation grade and also the lymph node assessment. The
lymph node related factors are well described in the earlier
cancer stages but less explored in stage IV. The lymph
node ratio has been shown to a significant marker for the
prognosis within stage III disease [10,22]. The ratio is a
continuous variable but a grouping makes it more defined
and facilitates the identification of risk groups. It could
possibly give an indication on the tumour biology and
thus also the total cancer burden. In our material we
found a significant difference in median survival between
LNR-groups 1 and 3 of almost one year. We noted that the
possible long term survivors were mainly from LNR-group
1.
The lymph node ratio can be seen and used as a prognos-
tic indicator. In our opinion a high quota can indicate a
high risk that there is more of a disseminated disease.
Thus, LNR-group 3 (with high quota) could be seen as a
marker of having a higher risk of a metastatic growth that
is not yet detectable by radiology. A high ratio also corre-
lates to a higher risk of multiple metastasis locations and
to a worse differentiation grade and often worse response
to chemotherapy. All these factors add up towards a worse
prognosis. This can then lead to a high risk of early "recur-
rence" and worse response to treatment. The prognostic
indication could be an aid in the decision of the contin-
ued treatment. As discussed above it is possible to surgi-
cally treat the metastasis. However, it is not without risk
and should be carefully. Thus in our opinion the possible
candidates for curative intent should mainly be recruited
among the patients with low lymph node quotas, since
they could be more likely to benefit from the procedure.
As the LNR is a computation we would not call it a factor
in itself. The ratio figures can dependent on the number of
nodes assessed. The data and specific arithmetical num-
bers of a centre can thus often be unique. However, there
will still be a distribution among them which can range
from good to worse. The UICC/AJCC recommendation
for the assessment is set at 12 nodes. In an effort to com-
ply with this difficulty we did a second analysis, looking
at the patients with at least 12 assessed nodes. That the
result retained significance does strengthen the hypothesis
Cancer-specific survival in stage IV colorectal cancer by lymph nod  ratio group 1–3Figure 1
Cancer-specific survival in stage IV colorectal cancer 
by lymph node ratio group 1–3. Group 1 correspond to 
a low quota/ratio and 3 to a high ratio.
Table 2: Survival by lymph node ratio group and therapy 
eligibility (median in days with upper/lower 95%)
LNR group Chemotherapy eligibility All
Yes No
1 791 (538–864) 209 (144–757) 708 (298–824)
2 588 (349–745) 331 (271–514) 438 (346–688)
3 433 (281–488) 91 (26–173) 277 (173–473)
Total 538 (467–708) 229 (168–345) 431 (338–502)Page 4 of 6
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lymph node data. We believe that this material shows that
there is information of importance in the node assess-
ment even in stage IV and that the data should be
requested. Interestingly, the N-status was not significant
whilst the ratio was. An explanation could be that the lat-
ter also is affected by the differentiation grade. Another
reason could be that the N2 only marks more than 3 pos-
itive nodes and thus lack the possibility to distinguish fur-
ther details.
In our opinion, this material can show that the lymph
node ratio could give an indication of the prognosis also
in stage IV colorectal cancer. It is a rather simple method
for getting a prognostic hint. However, in this heterogene-
ous group we do not want to point out or promote only
one single factor. Rather we want to show how important
the multidisciplinary approach is and that there is a large
amount of information to be considered for treatment
decisions. The inherent survival variability is great within
the stage group. It is not fully covered within the limita-
tions of the TNM-system and modifications have been
suggested [23]. Additional pathology information,
including lymph node data, would be of interest when
reporting from treatment studies in this patient group. It
could then provide further details about the patient selec-
tion and how we can interpret the new knowledge. One
weakness in our material is the relatively small number of
patients and that the study is retrospective. However, we
believe this to be well compensated by the fact that the
material is unselected and population based. All were
included, registered and treated using the same guide-
lines.
Conclusion
Stage IV colorectal cancer is a heterogeneous group regard-
ing the survival prognosis. The lymph node ratio was
found to be a significant marker for the survival prognosis
(p < 0.0049). High and low risk groups could be identi-
fied with a survival difference of up to one year. It could
be of importance when planning a treatment strategy or
evaluating clinical data materials. A pathology report
should include a node assessment even at presence of syn-
chronous metastasis.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KD was involved in the concept and design, data collec-
tion, analysis and interpretation and preparation of the
manuscript. BG was involved in the concept and design,
data collection, analysis and interpretation and prepara-
tion of the manuscript. Both authors read and approved
the final manuscript
Acknowledgements
We like to express our gratitude to the staff of our oncology laboratory 
unit assisting in the collection and registration of data and samples. Our 
thanks to the Anna-Lisa and Bror Björnsson Foundation for a scholarship 
grant.
References
1. Health SNBo: Incidence of cancer in Sweden.  2001.
2. Greene FL: Staging of colon and rectal cancer: from endos-
copy to molecular markers.  Surg Endosc 2006, 20(Suppl
2):S475-478.
3. Daniels IR, Fisher SE, Heald RJ, Moran BJ: Accurate staging, selec-
tive preoperative therapy and optimal surgery improves
outcome in rectal cancer: a review of the recent evidence.
Colorectal Dis 2007, 9:290-301.
4. UICC/AJCC: TNM Classification of Malignant Tumors, fifth
edition (1997).  1997.
5. Yun HR, Lee WY, Lee OS, Cho YB, Yun SH, Chun HK: The prog-
nostic factors of stage IV colorectal cancer and assessment
of proper treatment according to the patient's status.  Int J
Colorectal Dis 2007, 22(11):1301-1310.
6. Kehoe J, Khatri VP: Staging and prognosis of colon cancer.  Surg
Oncol Clin N Am 2006, 15:129-146.
7. Dhar DK, Yoshimura H, Kinukawa N, Maruyama R, Tachibana M,
Kohno H, Kubota H, Nagasue N: Metastatic lymph node size and
colorectal cancer prognosis.  J Am Coll Surg 2005, 200:20-28.
8. Berberoglu U: Prognostic significance of total lymph node
number in patients with T1-4N0M0 colorectal cancer.  Hepa-
togastroenterology 2004, 51:1689-1693.
9. Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald
JS, Catalano PJ, Haller DG: Colon cancer survival is associated
with decreasing ratio of metastatic to examined lymph
nodes.  J Clin Oncol 2005, 23:8706-8712.
10. Lee HY, Choi HJ, Park KJ, Shin JS, Kwon HC, Roh MS, Kim C: Prog-
nostic Significance of Metastatic Lymph Node Ratio in Node-
Positive Colon Carcinoma.  Ann Surg Oncol 2007,
14(5):1712-1717.
11. oncology Rco: Regional guidelines for colorectal cancer.  2006.
12. Ragnhammar P, Hafstrom L, Nygren P, Glimelius B: A systematic
overview of chemotherapy effects in colorectal cancer.  Acta
Oncol 2001, 40:282-308.
13. Turrini O, Viret F, Guiramand J, Lelong B, Bege T, Delpero JR: Strat-
egies for the treatment of synchronous liver metastasis.  Eur
J Surg Oncol 2007, 33:735-740.
14. Iizasa T, Suzuki M, Yoshida S, Motohashi S, Yasufuku K, Iyoda A,
Shibuya K, Hiroshima K, Nakatani Y, Fujisawa T: Prediction of
prognosis and surgical indications for pulmonary metasta-
sectomy from colorectal cancer.  Ann Thorac Surg 2006,
82:254-260.
15. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamil-
ton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML,
Sargent DJ, Taylor CR, Welton M, Willett C: Prognostic factors in
colorectal cancer. College of American Pathologists Con-
sensus Statement 1999.  Arch Pathol Lab Med 2000, 124:979-994.
16. Fakih MG, Padmanabhan A: CEA monitoring in colorectal can-
cer. What you should know.  Oncology (Williston Park) 2006,
20:579-587. discussion 588, 594, 596 passim.
17. Mori T, Hirota T, Ohashi Y, Kodaira S: Significance of histologic
type of primary lesion and metastatic lymph nodes as a prog-
nostic factor in stage III colon cancer.  Dis Colon Rectum 2006,
49:982-992.
18. Kuo LJ, Leu SY, Liu MC, Jian JJ, Hongiun Cheng S, Chen CM: How
aggressive should we be in patients with stage IV colorectal
cancer?  Dis Colon Rectum 2003, 46:1646-1652.
19. Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD:
Nonoperative management of primary colorectal cancer in
patients with stage IV disease.  Ann Surg Oncol 1999, 6:651-657.
20. Jones OM, John SK, Horseman N, Lawrance RJ, Fozard JB: Cause
and place of death in patients dying with colorectal cancer.
Colorectal Dis 2007, 9:253-257.
21. Choi JS, Choo SW, Park KB, Shin SW, Yoo SY, Kim JH, Do YS: Inter-
ventional management of malignant colorectal obstruction:Page 5 of 6
(page number not for citation purposes)
World Journal of Surgical Oncology 2008, 6:127 http://www.wjso.com/content/6/1/127Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
use of covered and uncovered stents.  Korean J Radiol 2007,
8:57-63.
22. Derwinger K, Carlsson G, Gustavsson B: A study of lymph node
ratio as a prognostic marker in colon cancer.  Eur J Surg Oncol
2008, 34:771-775.
23. Poston GJ, Figueras J, Giuliante F, Nuzzo G, Sobrero AF, Gigot JF,
Nordlinger B, Adam R, Gruenberger T, Choti MA, Bilchik AJ, Van
Cutsem EJ, Chiang JM, D'Angelica MI: Urgent need for a new stag-
ing system in advanced colorectal cancer.  J Clin Oncol 2008,
26:4828-4833.Page 6 of 6
(page number not for citation purposes)
